Symbols / CHRS
CHRS Chart
About
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 256.34M |
| Enterprise Value | 64.51M | Income | 61.03M | Sales | 277.73M |
| Book/sh | 0.76 | Cash/sh | 1.59 | Dividend Yield | — |
| Payout | 0.00% | Employees | 158 | IPO | — |
| P/E | 3.12 | Forward P/E | -3.50 | PEG | — |
| P/S | 0.92 | P/B | 2.27 | P/C | — |
| EV/EBITDA | -0.81 | EV/Sales | 0.23 | Quick Ratio | 1.19 |
| Current Ratio | 1.24 | Debt/Eq | 61.89 | LT Debt/Eq | — |
| EPS (ttm) | 0.55 | EPS next Y | -0.49 | EPS Growth | — |
| Revenue Growth | 91.20% | Earnings | 2026-03-10 | ROA | -10.26% |
| ROE | — | ROIC | — | Gross Margin | 56.31% |
| Oper. Margin | -3.65% | Profit Margin | 55.80% | Shs Outstand | 149.47M |
| Shs Float | 108.52M | Short Float | 25.42% | Short Ratio | 9.22 |
| Short Interest | — | 52W High | 2.62 | 52W Low | 0.71 |
| Beta | 1.02 | Avg Volume | 2.08M | Volume | 280.70K |
| Target Price | $6.75 | Recom | None | Prev Close | $1.67 |
| Price | $1.72 | Change | 2.69% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.75
Mean price target
2. Current target
$1.72
Latest analyst target
3. DCF / Fair value
$3.57
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.72
Low
$4.00
High
$10.00
Mean
$6.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-22 | init | Oppenheimer | — → Outperform | $10 |
| 2025-09-04 | up | Maxim Group | Hold → Buy | $4 |
| 2025-04-29 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-04-24 | main | UBS | Neutral → Neutral | $1 |
| 2025-03-11 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-01-23 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-01-22 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-12-05 | main | Baird | Outperform → Outperform | $6 |
| 2024-12-04 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-08 | main | Baird | Outperform → Outperform | $4 |
| 2024-11-07 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-09-16 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-08-16 | down | UBS | Buy → Neutral | $2 |
| 2024-08-05 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-07-01 | main | Baird | Outperform → Outperform | $8 |
| 2024-05-24 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-05-13 | main | Truist Securities | Buy → Buy | $7 |
| 2024-05-10 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-03-20 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-03-14 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
- Coherus investor talks stream online from Boston and Miami - Stock Titan Mon, 23 Feb 2026 14
- Coherus Oncology files prospectus to offer up to $64.9 million in stock - Investing.com Fri, 23 Jan 2026 08
- Coherus Oncology (CHRS) Taps ATM Facility: Strategic Lifeline or Dilution Trade-Off for Its Pipeline? - simplywall.st Mon, 26 Jan 2026 08
- Coherus Oncology (CHRS) Is Up 28.7% After ATM Offering And Bullish Coverage - What's Changed - Yahoo Finance Sun, 25 Jan 2026 08
- Coherus Oncology: A Two-Pronged March With Mid-2026 Implications (CHRS) - Seeking Alpha ue, 23 Dec 2025 08
- Oncology biotech Coherus raises $50M for LOQTORZI and clinical programs - Stock Titan ue, 17 Feb 2026 21
- Coherus Biosciences Updates ATM Equity Offering Program - TipRanks Fri, 23 Jan 2026 08
- Coherus BioSciences stock falls after pricing $50.1 million share offering - Investing.com Fri, 13 Feb 2026 08
- There's No Escaping Coherus Oncology, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 27% Share Price Rise - simplywall.st Sat, 10 Jan 2026 08
- Coherus Oncology: Five Readouts Or More Possible In 2026 - Seeking Alpha Wed, 01 Oct 2025 07
- Coherus plans stock sale to fund LOQTORZI commercialization - Stock Titan hu, 12 Feb 2026 08
- Need To Know: Analysts Are Much More Bullish On Coherus Oncology, Inc. (NASDAQ:CHRS) Revenues - Yahoo Finance Sun, 10 Aug 2025 07
- Coherus Oncology stock soars 35% after Oppenheimer initiates with massive upside - Investing.com Fri, 23 Jan 2026 08
- Despite shrinking by US$22m in the past week, Coherus Oncology (NASDAQ:CHRS) shareholders are still up 122% over 1 year - simplywall.st ue, 28 Oct 2025 07
- Cancer-drug firm Coherus to raise $50M for LOQTORZI, clinical development - Stock Titan hu, 12 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 375000 | — | — | Stock Award(Grant) at price 0.00 per share. | LANFEAR DENNIS M | Chief Executive Officer | — | 2026-01-23 00:00:00 | D |
| 1 | 112500 | — | — | Stock Award(Grant) at price 0.00 per share. | MCMICHAEL BRYAN J | Chief Financial Officer | — | 2026-01-22 00:00:00 | D |
| 2 | 99988 | 73881 | — | Sale at price 0.74 per share. | WAHLSTROM MATS | Director | — | 2025-05-23 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -103.02M | -193.94M | -249.36M | -260.69M |
| TotalUnusualItems | 163.96M | 0.00 | -6.22M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 163.96M | 0.00 | -6.22M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | 28.51M | -237.89M | -291.75M | -287.10M |
| ReconciledDepreciation | 5.28M | 3.79M | 3.70M | 3.45M |
| ReconciledCostOfRevenue | 117.55M | 158.99M | 70.08M | 57.59M |
| EBITDA | 60.94M | -193.94M | -255.58M | -260.69M |
| EBIT | 55.66M | -197.73M | -259.28M | -264.14M |
| NetInterestIncome | -27.16M | -40.54M | -32.47M | -22.96M |
| InterestExpense | 27.16M | 40.54M | 32.47M | 22.96M |
| NormalizedIncome | -135.45M | -237.89M | -285.53M | -287.10M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 28.51M | -237.89M | -291.75M | -287.10M |
| TotalExpenses | 378.63M | 460.44M | 467.92M | 590.41M |
| TotalOperatingIncomeAsReported | -111.67M | -203.20M | -256.88M | -263.86M |
| DilutedAverageShares | 114.83M | 94.16M | 77.63M | 75.45M |
| BasicAverageShares | 114.55M | 94.16M | 77.63M | 75.45M |
| DilutedEPS | 0.25 | -2.53 | -3.76 | -3.81 |
| BasicEPS | 0.25 | -2.53 | -3.76 | -3.81 |
| DilutedNIAvailtoComStockholders | 28.51M | -237.89M | -291.75M | -287.10M |
| AverageDilutionEarnings | 0.00 | 0.00 | ||
| NetIncomeCommonStockholders | 28.51M | -237.89M | -291.75M | -287.10M |
| NetIncome | 28.51M | -237.89M | -291.75M | -287.10M |
| NetIncomeIncludingNoncontrollingInterests | 28.51M | -237.89M | -291.75M | -287.10M |
| NetIncomeContinuousOperations | 28.51M | -237.89M | -291.75M | -287.10M |
| TaxProvision | 0.00 | -380.00K | 0.00 | 0.00 |
| PretaxIncome | 28.51M | -238.27M | -291.75M | -287.10M |
| OtherIncomeExpense | 167.33M | 5.47M | -2.40M | -283.00K |
| OtherNonOperatingIncomeExpenses | 3.37M | 5.47M | 3.82M | -283.00K |
| SpecialIncomeCharges | 163.96M | 0.00 | -6.22M | 0.00 |
| GainOnSaleOfBusiness | 176.59M | 0.00 | 0.00 | |
| OtherSpecialCharges | 12.63M | 6.22M | ||
| NetNonOperatingInterestIncomeExpense | -27.16M | -40.54M | -32.47M | -22.96M |
| InterestExpenseNonOperating | 27.16M | 40.54M | 32.47M | 22.96M |
| OperatingIncome | -111.67M | -203.20M | -256.88M | -263.86M |
| OperatingExpense | 261.07M | 301.45M | 397.84M | 532.82M |
| ResearchAndDevelopment | 93.34M | 109.44M | 199.36M | 363.11M |
| SellingGeneralAndAdministration | 167.74M | 192.01M | 198.48M | 169.71M |
| GrossProfit | 149.41M | 98.25M | 140.96M | 268.96M |
| CostOfRevenue | 117.55M | 158.99M | 70.08M | 57.59M |
| TotalRevenue | 266.96M | 257.24M | 211.04M | 326.55M |
| OperatingRevenue | 266.96M | 257.24M | 211.04M | 326.55M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 115.61M | 112.22M | 78.85M | 76.93M |
| ShareIssued | 115.61M | 112.22M | 78.85M | 76.93M |
| NetDebt | 138.94M | 370.48M | 407.51M | |
| TotalDebt | 269.90M | 480.84M | 480.42M | 419.02M |
| TangibleBookValue | -185.64M | -265.10M | -143.35M | 94.16M |
| InvestedCapital | 132.94M | 279.94M | 333.64M | 506.01M |
| WorkingCapital | 58.60M | 143.86M | 242.54M | 437.00M |
| NetTangibleAssets | -185.64M | -265.10M | -143.35M | 94.16M |
| CapitalLeaseObligations | 4.98M | 7.47M | 9.36M | 10.74M |
| CommonStockEquity | -131.99M | -193.43M | -137.42M | 97.73M |
| TotalCapitalization | 132.94M | 279.94M | 333.64M | 506.01M |
| TotalEquityGrossMinorityInterest | -131.99M | -193.43M | -137.42M | 97.73M |
| StockholdersEquity | -131.99M | -193.43M | -137.42M | 97.73M |
| GainsLossesNotAffectingRetainedEarnings | -275.00K | -248.00K | -249.00K | -270.00K |
| OtherEquityAdjustments | -275.00K | -248.00K | -249.00K | -270.00K |
| RetainedEarnings | -1.55B | -1.58B | -1.34B | -1.05B |
| AdditionalPaidInCapital | 1.42B | 1.39B | 1.20B | 1.15B |
| CapitalStock | 12.00K | 11.00K | 8.00K | 7.00K |
| CommonStock | 12.00K | 11.00K | 8.00K | 7.00K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 580.52M | 823.03M | 618.26M | 581.61M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 297.54M | 491.26M | 479.57M | 416.28M |
| OtherNonCurrentLiabilities | 28.23M | 11.46M | 3.47M | 750.00K |
| NonCurrentDeferredLiabilities | 1.10M | 1.10M | 0.00 | |
| NonCurrentDeferredTaxesLiabilities | 1.10M | 1.10M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 268.21M | 478.70M | 476.10M | 415.53M |
| LongTermCapitalLeaseObligation | 3.29M | 5.33M | 5.05M | 7.25M |
| LongTermDebt | 264.93M | 473.37M | 471.06M | 408.28M |
| CurrentLiabilities | 282.98M | 331.77M | 138.69M | 165.33M |
| OtherCurrentLiabilities | 14.77M | |||
| CurrentDebtAndCapitalLeaseObligation | 1.69M | 2.15M | 4.32M | 3.49M |
| CurrentCapitalLeaseObligation | 1.69M | 2.15M | 4.32M | 3.49M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 18.34M | 21.52M | 22.61M | 22.01M |
| PayablesAndAccruedExpenses | 248.18M | 308.11M | 111.77M | 139.82M |
| CurrentAccruedExpenses | 219.72M | 272.89M | 100.24M | 123.66M |
| Payables | 28.46M | 35.22M | 11.53M | 16.16M |
| AccountsPayable | 28.46M | 35.22M | 11.53M | 16.16M |
| TotalAssets | 448.53M | 629.60M | 480.85M | 679.33M |
| TotalNonCurrentAssets | 106.95M | 153.97M | 99.61M | 77.01M |
| OtherNonCurrentAssets | 50.47M | 77.18M | 84.93M | 65.64M |
| GoodwillAndOtherIntangibleAssets | 53.65M | 71.67M | 5.93M | 3.56M |
| OtherIntangibleAssets | 53.65M | 70.73M | 4.99M | 2.62M |
| Goodwill | 0.00 | 943.00K | 943.00K | 943.00K |
| NetPPE | 2.84M | 5.12M | 8.75M | 7.81M |
| AccumulatedDepreciation | -20.99M | -20.65M | -20.16M | -16.85M |
| GrossPPE | 23.82M | 25.77M | 28.91M | 24.66M |
| Leases | 5.75M | 5.75M | 6.20M | 5.94M |
| ConstructionInProgress | 0.00 | 696.00K | 388.00K | |
| OtherProperties | 2.29M | 4.63M | 2.29M | |
| MachineryFurnitureEquipment | 18.07M | 17.73M | 17.39M | 16.04M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 341.58M | 475.63M | 381.23M | 602.32M |
| OtherCurrentAssets | 11.53M | 11.10M | 22.92M | 10.80M |
| PrepaidAssets | 11.64M | 23.66M | 17.88M | 13.67M |
| Inventory | 70.09M | 62.60M | 38.79M | 37.64M |
| Receivables | 122.33M | 260.52M | 109.96M | 123.02M |
| OtherReceivables | 11.01M | |||
| AccountsReceivable | 111.32M | 260.52M | 109.96M | 123.02M |
| CashCashEquivalentsAndShortTermInvestments | 125.99M | 117.75M | 191.68M | 417.19M |
| OtherShortTermInvestments | 0.00 | 14.86M | 128.13M | 0.00 |
| CashAndCashEquivalents | 125.99M | 102.89M | 63.55M | 417.19M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -20.44M | -174.88M | -241.12M | -38.72M |
| RepaymentOfDebt | -260.39M | 0.00 | -190.75M | 0.00 |
| IssuanceOfDebt | 36.98M | 0.00 | 240.68M | 0.00 |
| IssuanceOfCapitalStock | 1.46M | 71.72M | 6.36M | 40.90M |
| CapitalExpenditure | -286.00K | -2.04M | -1.29M | |
| InterestPaidSupplementalData | 25.38M | 37.86M | 34.88M | 18.68M |
| IncomeTaxPaidSupplementalData | 40.00K | 1.22M | ||
| EndCashPosition | 126.25M | 103.34M | 63.99M | 417.63M |
| BeginningCashPosition | 103.34M | 63.99M | 417.63M | 541.60M |
| EffectOfExchangeRateChanges | 0.00 | |||
| ChangesInCash | 22.91M | 39.36M | -353.65M | -123.96M |
| FinancingCashFlow | -186.97M | 69.60M | 54.33M | 51.88M |
| CashFlowFromContinuingFinancingActivities | -186.97M | 69.60M | 54.33M | 51.88M |
| NetOtherFinancingCharges | 33.76M | -4.62M | -4.97M | -2.42M |
| ProceedsFromStockOptionExercised | 1.22M | 2.50M | 3.01M | 13.40M |
| NetCommonStockIssuance | 1.46M | 71.72M | 6.36M | 40.90M |
| CommonStockIssuance | 1.46M | 71.72M | 6.36M | 40.90M |
| NetIssuancePaymentsOfDebt | -223.41M | 0.00 | 49.93M | 0.00 |
| NetLongTermDebtIssuance | -223.41M | 0.00 | 49.93M | 0.00 |
| LongTermDebtPayments | -260.39M | 0.00 | -190.75M | 0.00 |
| LongTermDebtIssuance | 36.98M | 0.00 | 240.68M | 0.00 |
| InvestingCashFlow | 230.32M | 144.64M | -166.85M | -138.41M |
| CashFlowFromContinuingInvestingActivities | 230.32M | 144.64M | -166.85M | -138.41M |
| NetOtherInvestingChanges | 110.00K | -492.00K | -4.47M | -136.00M |
| NetInvestmentPurchaseAndSale | 14.89M | 138.13M | -127.38M | -1.12M |
| SaleOfInvestment | 14.89M | 157.64M | 0.00 | 181.36M |
| PurchaseOfInvestment | 0.00 | -19.51M | -127.38M | -182.49M |
| NetBusinessPurchaseAndSale | 215.32M | 7.00M | -35.00M | 0.00 |
| SaleOfBusiness | 227.82M | 7.00M | 0.00 | 0.00 |
| PurchaseOfBusiness | -12.50M | 0.00 | -35.00M | |
| NetPPEPurchaseAndSale | 559.00K | -2.04M | -1.29M | |
| SaleOfPPE | 845.00K | 0.00 | 0.00 | |
| PurchaseOfPPE | -286.00K | -2.04M | -1.29M | |
| OperatingCashFlow | -20.44M | -174.88M | -241.12M | -37.43M |
| CashFlowFromContinuingOperatingActivities | -20.44M | -174.88M | -241.12M | -37.43M |
| ChangeInWorkingCapital | 55.89M | -36.83M | -79.26M | 42.36M |
| ChangeInOtherWorkingCapital | 596.00K | -230.00K | ||
| ChangeInPayablesAndAccruedExpense | -65.33M | 142.41M | -27.32M | 16.07M |
| ChangeInAccruedExpense | -61.39M | 118.65M | -22.77M | 15.20M |
| ChangeInPayable | -3.94M | 23.76M | -4.55M | 874.00K |
| ChangeInAccountPayable | -3.94M | 23.76M | -4.55M | 874.00K |
| ChangeInPrepaidAssets | 3.83M | 18.18M | -17.64M | -1.52M |
| ChangeInInventory | -31.95M | -46.73M | -47.35M | -6.25M |
| ChangeInReceivables | 149.35M | -150.68M | 13.05M | 34.06M |
| ChangesInAccountReceivables | 149.35M | -150.68M | 13.05M | 34.06M |
| OtherNonCashItems | 82.00K | -37.00K | 8.23M | 143.05M |
| StockBasedCompensation | 27.80M | 43.11M | 50.74M | 51.36M |
| AssetImpairmentCharge | 20.91M | 52.59M | 26.00M | 8.34M |
| AmortizationOfSecurities | -3.05M | -730.00K | 1.09M | |
| DepreciationAmortizationDepletion | 5.28M | 3.79M | 3.70M | 3.45M |
| DepreciationAndAmortization | 5.28M | 3.79M | 3.70M | 3.45M |
| OperatingGainsLosses | -158.92M | 375.00K | 41.22M | |
| GainLossOnInvestmentSecurities | 5.04M | 375.00K | 35.00M | |
| GainLossOnSaleOfBusiness | -176.59M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | 28.51M | -237.89M | -291.75M | -287.10M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CHRS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|